• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

German billionaire Hopp readies sale of skin patch maker LTS

April 6, 2017 By Sarah Faulkner

German billionaire Hopp readies sale of skin patch maker LTSGerman billionaire Dietmar Hopp is reportedly preparing to sell medical skin patch maker LTS Lohmann as he looks to shake-up his investment porfolio.

LTS has 1,300 employees and brings in more than 300 million euros ($319 million) in annual sales from nicotine and medical patches that treat conditions such as Parkinson’s and restless legs syndrome. Sources close to the matter told Reuters that Hopps’ investment firm, Dievini, has begun to approach potential buyers and gauge their interest in LTS.

Hopp, the co-founder of software group SAP, shared joint ownership of LTS with Novartis (NYSE:NVS) and German investment firm BWK until 2014, when he bought them out in a deal valuaing LTS at 1.2 billion euros ($1.3 billion). At the time, Hopp was unable to find a 3rd-party buyer for the medical skin patch business.

Dievini was not available for comment, Reuters reported.

In 2014, Evonik was in exclusive talks to buy LTS but pulled out at the last minute after a disagreement on the price. Hopp is unlikely to be able to reignite interest from Evonik, as the German chemicals group has shifted its focus to acquiring specialty chemical companies.

According to sources familiar with the matter, private equity groups have begun seeking advice from external legal and financial consultants on a possible bid for LTS.

Wendel of France and Sweden’s Nordic Capital made a bid for LTS in 2014, but it’s not clear if either 1 of those groups will return with a new offer.

Material from Reuters was used in this report.

Filed Under: Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: LTS Lohmann, Novartis

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS